Acurela Pharms Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 263.02%
- Profit Growth -275.91%
- Ebitda -258.20%
- Net Worth -576.82%
- Total Assets 219.67%
About Acurela Pharms
Acurela Pharms Limited (APL) is a Public Limited Indian Non-Government Company incorporated in India on 20 July 2021 (Three years and six months 23 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Shivapura Gangadhar, Thushar Gangadhar, and Chinnappa Shankar serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24290KA2021PLC149702
-
Company No.
149702
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
20 Jul 2021
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Acurela Pharms?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Thushar Gangadhar
|
Managing Director | 20-Jul-2021 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Shivapura Gangadhar
|
Director | 20-Jul-2021 | Current |
|
Chinnappa Shankar
|
Director | 20-Jul-2021 | Current |
Financial Performance of Acurela Pharms.
Acurela Pharms Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 263.02% increase. The company also saw a substantial fall in profitability, with a 275.91% decrease in profit. The company's net worth observed a substantial decline by a decrease of 576.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Acurela Pharms?
In 2023, Acurela Pharms had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Acurela Health LimitedShivapura Gangadhar and Thushar Gangadhar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Acurela Pharms?
Acurela Pharms has a workforce of 27 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Acurela Pharms, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Acurela Pharms's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.